SWOG clinical trial number
SWOG-9133

Randomized Trial of Subtotal Nodal Irradiation Versus Doxorubicin Plus Vinblastine and Subtotal Nodal Irradiation for Stage I-IIA Hodgkin's Disease, Phase III

Closed
Phase
Accrual
75%
Published
Abbreviated Title
Subtotal Nodal Irradiation vs Doxorubicin+Vinblastine+Subtotal Nodal Irradiation
Activated
09/15/1992
Closed
04/24/2000
Participants
NCORP, Members, Medical Oncologists, Pathologists, CALGB

Research committees

Lymphoma

Treatment

Adriamycin® Doxorubicin Vinblastine Sulfate Radiation Therapy

Eligibility Criteria Expand/Collapse

Biopsy proven Stages I-IIA Hodgkin's disease; no staging lap; bidimen. measurable disease; no mediastinal mass >= 1/3 max. thoracic diameter; no infradiaphragmatic presentations; no prior chemo or RT; no AIDS or HIV.

Publication Information Expand/Collapse

2018

Value of Anti-Cancer Drugs in SWOG Phase III Clinical Trials: Evidence from Multiple Evaluation Mechanisms

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster #B-335

2017

Seven year follow-up for energy/vitality outcomes in early stage hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208

C Moinpour;J Unger;P Ganz;T Wang;A Kornblith;E Gaynor;MA Bowers;S Balcerzak;G Gatti Gunderson;Mark Kaminski;H Erba;O Press;RI Fisher Journal of Cancer Survivorship:Research and Practice, 2017 Feb;11(1):32-40; 2016 Jul 12 [Epub ahead of print]

PMid: PMID27405732 | PMC number: PMC5233644

2008

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

2007

Use of patient-reported outcomes in phase III cancer treatment trials: lessons learned and future directions

PA Ganz;CC Gotay Journal of Clinical Oncology 25(32):5063-9

PMid: PMID17991922

2001

Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA-IIA Hodgkin's disease

OW Press;M LeBlanc;AS Lichter;TM Grogan;JM Unger;T Wasserman;E Gaynor;BA Peterson;TP Miller;RI Fisher Journal of Clinical Oncology 19(22):4238-4244

A phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for Stage IA-IIA Hodgkin's disease (SWOG 9133, CALGB 9391)

OW Press;M LeBlanc;A Lichter;TH Wasserman;J Unger;T Miller;RI Fisher Leukemia & Lymphoma 42(Suppl.2):52(#P-089)

2000

A phase III randomized intergroup trial of subtotal lymphoid irradiation (STLI) versus doxorubicin, vinblastine, and STLI for stage IA-IIA Hodgkin's disease (SWOG 9133, CALGB 9391)

OW Press;M LeBlanc;A Lichter;TH Wassermann;T Miller;R Fisher Blood 96(11):575a(#2471)

Other Clinical Trials

SWOG Clinical Trial Number
S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase
SWOG Clinical Trial Number
S2114

A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
02/23/2023
Accrual
15%
Open
Phase